BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 26429872)

  • 1. Application of functional vincristine plus dasatinib liposomes to deletion of vasculogenic mimicry channels in triple-negative breast cancer.
    Zeng F; Ju RJ; Liu L; Xie HJ; Mu LM; Zhao Y; Yan Y; Hu YJ; Wu JS; Lu WL
    Oncotarget; 2015 Nov; 6(34):36625-42. PubMed ID: 26429872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liposomes, modified with PTD(HIV-1) peptide, containing epirubicin and celecoxib, to target vasculogenic mimicry channels in invasive breast cancer.
    Ju RJ; Li XT; Shi JF; Li XY; Sun MG; Zeng F; Zhou J; Liu L; Zhang CX; Zhao WY; Lu WL
    Biomaterials; 2014 Aug; 35(26):7610-21. PubMed ID: 24912818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-angiogenic treatment promotes triple-negative breast cancer invasion via vasculogenic mimicry.
    Sun H; Zhang D; Yao Z; Lin X; Liu J; Gu Q; Dong X; Liu F; Wang Y; Yao N; Cheng S; Li L; Sun S
    Cancer Biol Ther; 2017 Apr; 18(4):205-213. PubMed ID: 28278077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy in Treating Lung Metastasis of Invasive Breast Cancer with Functional Vincristine Plus Dasatinib Liposomes.
    Zeng F; Ju RJ; Liu L; Xie HJ; Mu LM; Lu WL
    Pharmacology; 2018; 101(1-2):43-53. PubMed ID: 28988243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Destruction of vasculogenic mimicry channels by targeting epirubicin plus celecoxib liposomes in treatment of brain glioma.
    Ju RJ; Zeng F; Liu L; Mu LM; Xie HJ; Zhao Y; Yan Y; Wu JS; Hu YJ; Lu WL
    Int J Nanomedicine; 2016; 11():1131-46. PubMed ID: 27042063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting Epirubicin Plus Quinacrine Liposomes Modified with DSPE-PEG2000-C(RGDfK) Conjugate for Eliminating Invasive Breast Cancer.
    Sun MG; Shi JF; Li XY; Zhao Y; Ju RJ; Mu LM; Yan Y; Li XT; Zeng F; Lu WL
    J Biomed Nanotechnol; 2015 Aug; 11(8):1339-53. PubMed ID: 26295137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Combination of Targeted Sunitinib Liposomes and Targeted Vinorelbine Liposomes for Treating Invasive Breast Cancer.
    Shi JF; Sun MG; Li XY; Zhao Y; Ju RJ; Mu LM; Yan Y; Li XT; Zeng F; Lu WL
    J Biomed Nanotechnol; 2015 Sep; 11(9):1568-82. PubMed ID: 26485927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of Vasculogenic Mimicry and Angiogenesis by an Anti-EGFR IgG1-Human Endostatin-P125A Fusion Protein Reduces Triple Negative Breast Cancer Metastases.
    Shin SU; Cho HM; Das R; Gil-Henn H; Ramakrishnan S; Al Bayati A; Carroll SF; Zhang Y; Sankar AP; Elledge C; Pimentel A; Blonska M; Rosenblatt JD
    Cells; 2021 Oct; 10(11):. PubMed ID: 34831127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor efficacy of Lf modified daunorubicin plus honokiol liposomes in treatment of brain glioma.
    Liu S; Zhang SM; Ju RJ; Xiao Y; Wang X; Song XL; Gu LY; Cheng L; Li XT; Chen GR
    Eur J Pharm Sci; 2017 Aug; 106():185-197. PubMed ID: 28583810
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Twist1 expression induced by sunitinib accelerates tumor cell vasculogenic mimicry by increasing the population of CD133+ cells in triple-negative breast cancer.
    Zhang D; Sun B; Zhao X; Ma Y; Ji R; Gu Q; Dong X; Li J; Liu F; Jia X; Leng X; Zhang C; Sun R; Chi J
    Mol Cancer; 2014 Sep; 13():207. PubMed ID: 25200065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanosized functional miRNA liposomes and application in the treatment of TNBC by silencing Slug gene.
    Yan Y; Li XQ; Duan JL; Bao CJ; Cui YN; Su ZB; Xu JR; Luo Q; Chen M; Xie Y; Lu WL
    Int J Nanomedicine; 2019; 14():3645-3667. PubMed ID: 31190817
    [No Abstract]   [Full Text] [Related]  

  • 12. Cetuximab PET delineated changes in cellular distribution of EGFR upon dasatinib treatment in triple negative breast cancer.
    McKnight BN; Kim S; Boerner JL; Viola NT
    Breast Cancer Res; 2020 Apr; 22(1):37. PubMed ID: 32295603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of WT1 isoforms in vasculogenic mimicry and metastatic potential of human triple negative breast cancer cells.
    Bissanum R; Lirdprapamongkol K; Svasti J; Navakanitworakul R; Kanokwiroon K
    Biochem Biophys Res Commun; 2017 Dec; 494(1-2):256-262. PubMed ID: 29024629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipid nanocarriers of a lipid-conjugated estrogenic derivative inhibit tumor growth and enhance cisplatin activity against triple-negative breast cancer: pharmacokinetic and efficacy evaluation.
    Andey T; Sudhakar G; Marepally S; Patel A; Banerjee R; Singh M
    Mol Pharm; 2015 Apr; 12(4):1105-20. PubMed ID: 25661724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiosensitization with combined use of olaparib and PI-103 in triple-negative breast cancer.
    Jang NY; Kim DH; Cho BJ; Choi EJ; Lee JS; Wu HG; Chie EK; Kim IA
    BMC Cancer; 2015 Mar; 15():89. PubMed ID: 25884663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multifunctional liposomes loaded with paclitaxel and artemether for treatment of invasive brain glioma.
    Li XY; Zhao Y; Sun MG; Shi JF; Ju RJ; Zhang CX; Li XT; Zhao WY; Mu LM; Zeng F; Lou JN; Lu WL
    Biomaterials; 2014 Jul; 35(21):5591-604. PubMed ID: 24726749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multi-targeting NGR-modified liposomes recognizing glioma tumor cells and vasculogenic mimicry for improving anti-glioma therapy.
    Huang D; Zhang S; Zhong T; Ren W; Yao X; Guo Y; Duan XC; Yin YF; Zhang SS; Zhang X
    Oncotarget; 2016 Jul; 7(28):43616-43628. PubMed ID: 27283987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyaluronic acid modified daunorubicin plus honokiol cationic liposomes for the treatment of breast cancer along with the elimination vasculogenic mimicry channels.
    Ju RJ; Cheng L; Qiu X; Liu S; Song XL; Peng XM; Wang T; Li CQ; Li XT
    J Drug Target; 2018 Nov; 26(9):793-805. PubMed ID: 29334266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Granzyme B-based cytolytic fusion protein targeting EpCAM specifically kills triple negative breast cancer cells in vitro and inhibits tumor growth in a subcutaneous mouse tumor model.
    Amoury M; Kolberg K; Pham AT; Hristodorov D; Mladenov R; Di Fiore S; Helfrich W; Kiessling F; Fischer R; Pardo A; Thepen T; Hussain AF; Nachreiner T; Barth S
    Cancer Lett; 2016 Mar; 372(2):201-9. PubMed ID: 26806809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aptamer-mediated impairment of EGFR-integrin αvβ3 complex inhibits vasculogenic mimicry and growth of triple-negative breast cancers.
    Camorani S; Crescenzi E; Gramanzini M; Fedele M; Zannetti A; Cerchia L
    Sci Rep; 2017 Apr; 7():46659. PubMed ID: 28425453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.